First Patient enrolled in Phase II Clinical Study Evaluating THR-317 for treatment of MacTel 1
The study evaluates the efficacy and safety of THR-317 for the treatment of Macular Telangiectasia Type 1. This is a rare disease that affects the macula and can lead to vision loss.
First Patient enrolled in Phase I Clinical Trial of THR-687 for Treatment of DME
Preclinical studies have demonstrated the role of THR-687 (a pan RGD integrin antagonist) in targeting multiple aspects of retinal disease such as vessel leakage, inflammation, and neovascularization.
Initiation of a Phase II clinical trial, evaluating THR-317 incombination with Lucentis (anti-VEGF)
The company announces positive data from THR-317 Phase I/IIa clinical trial
The data confirm a good safety and tolerability of THR-317, and a clinically relevant biological activity.
First patients recruited in a Phase I/IIa clinical trial evaluating THR-317 (anti-PlGF) for treatment of DME.
The company regains full global commercial rights to its product JETREA®
Through an agreement with Novartis, the company regains full global commercial rights to JETREA®. Under the terms of the agreement, the company receives a forthcoming equity investment of €10 million.
Oncurious recruits first patient in trial with TB-403
Oncurious recruits its first patient in a Phase I/IIa clinical trial evaluating TB-403 (anti-PlGF) for treatment of medulloblastoma, a rare and life-threatening brain tumor that affects children.
The company unveils novel disease-modifying approaches for diabetic eye diseas
The approach has a current focus on diabetic eye disease, mainly diabetic retinopathy/diabetic macular edema, while providing a platform to develop therapies for other ophthalmological indications.
New pathways: drug development for diabetic eye disease
In 2015, ThromboGenics took a strategic decision to focus its resources on drug development. This decision was driven by the significant potential of our exciting and broad pipeline of next-generation medicines targeting the diabetic eye disease market.
JETREA® approval in over 50 countries worldwide
JETREA® approval in over 50 countries, with patients being treated in over 20 countries globally
EU approval and commercial launch of JETREA® outside the U.S.
European Medicines Agency (EMA) approves JETREA® (Ocriplasmin) for the Treatment of vitreomacular traction (VMT). Alcon launches JETREA in the first markets in Europe.
Commercial launch of JETREA® in the U.S.
ThromboGenics, Inc kicks off JETREA® commercialization in the US – JETREA is globally the first and only pharmacological treatment option for treating symptomatic VMA.
US FDA Approval for ocriplasmin
The FDA approves ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA) in the United States.
Ocriplasmin for vitreoretinal indications
The company starts to develop ocriplasmin for vitreoretinal indications such as symptomatic vitreomacular adhesion/traction.
ThromboGenics listed on Euronext Brussels
ThromboGenics nv raises €35 million through a successful Initial Public Offering (IPO) and listed on Euronext Brussels (THR: €4,64).
ThromboGenics broadens the company's R&D scope to include cardiovascular, oncology and ophthalmology programs in-licensed from the University of Leuven and the Flanders Institute for Biotechnology (VIB).
In 1991, Prof. Dr. Désiré Collen and colleagues at Katholieke Universiteit Leuven create Thromb-X NV, with an initial focus on the cardiovascular space.